Compare Atmos Energy Corporation (ATO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Atmos Energy Corporation trades at $170.2 (market cap $28.59B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Atmos Energy Corporation is far larger — about 364× Inovio Pharmaceuticals Inc's market cap, and Atmos Energy Corporation pays a 2.36% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ATO | INO | |
|---|---|---|
Market Cap | $28.59B | $78.55M |
Sector | Utilities | Health |
52-Week High | $192.25 | $2.87 |
52-Week Low | $162.44 | $0.66 |
Enterprise Value | $38.40B | $49.56M |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.68, up 1.05% today, with a bearish technical signal but strong fundamentals including a 28.5% net income margin and consistent dividend payments. Recent Q3 2026 earnings beat estimates with EPS of $1.43 versus $1.35 expected, and the company reaffirmed fiscal 2026 guidance. The stock shows neutral oscillators but bearish moving averages, with key support at $168.
The outlook is mixed: analyst consensus is a Buy with a $190.57 price target, but technical indicators suggest near-term caution. Risks include high capital expenditures impacting cash flow and interest rate sensitivity. Upside potential hinges on execution of rate hikes and infrastructure investments, while downside risks involve regulatory changes and economic slowdowns.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
